Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era

Abstract

The purpose of this study is to assess the likelihood of detecting stage T1a and T1b cancer in transurethral prostatectomy specimens during the PSA era. Comparison was made of transurethral resection of prostate (TURP) cohorts in the pre-PSA era (1986–1987) and the PSA era (1994–2000), excluding patients with known PCa. A total of 228 men without a known history of prostate cancer underwent TURP during the pre-PSA era time frame and 501 underwent the procedure during the PSA era time frame. Malignancy diagnosed at the time of TURP decreased from 14.9 to 5.2% of patients in the pre-PSA and PSA eras, respectively. Stage T1a decreased from 4.4 to 2.4% and Stage T1b decreased from 10.5 to 2.8% of patients in the pre-PSA and PSA eras, respectively (P<0.001, Fisher's exact test). Prostate cancer newly identified during TURP has decreased significantly in the era of PSA screening in our study population, with the most significant drop being in clinically significant stage T1b. The decrease in TURP rates reduces the overall incidence of T1a/b cancer but cannot explain the lower risk of detecting previously unsuspected cancer at the time of any given TURP. Identification of many men with occult prostate cancer before TURP through screening and early detection is the most likely cause of this finding. These data suggest that men considering surgical or medical management of benign prostatic hyperplasia may be informed that it should be infrequent that men properly evaluated for prostate cancer will harbor clinically significant undetected malignancy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928–934.

    Article  CAS  PubMed  Google Scholar 

  2. Endrizzi J, Optenberg S, Byers R, Thompson IM . Disappearance of well-differentiated carcinoma of the prostate: effect of transurethral resection of the prostate, prostate-specific antigen, and prostate biopsy. Urology 2001; 57: 733–736.

    Article  CAS  PubMed  Google Scholar 

  3. Ornstein DK, Rao GS, Smith DS, Andriole GL . The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880–883.

    Article  CAS  PubMed  Google Scholar 

  4. Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M . Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol 2005; 39: 289–293.

    Article  PubMed  Google Scholar 

  5. Moore GH, Lawshe B, Murphy J . Diagnosis of adenocarcinoma in transurethral resectates of the prostate gland. Am J Surg Pathol 1986; 10: 165–169.

    Article  CAS  PubMed  Google Scholar 

  6. Harkaway RC, Issa MM . Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2006; 9: 204–214.

    Article  CAS  PubMed  Google Scholar 

  7. Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA . Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150: 848–860.

    Article  CAS  PubMed  Google Scholar 

  8. Fowler Jr JE, Pandey P, Bigler SA, Yee DT, Kolski JM . Trends in diagnosis of stage T1a-b prostate cancer. J Urol 1997; 158: 1849–1852.

    Article  PubMed  Google Scholar 

  9. Meguro N, Maeda O, Saiki S, Kinouchi T, Kuroda M, Usami M et al. Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer. Hinyokika Kiyo 1998; 44: 639–643.

    CAS  PubMed  Google Scholar 

  10. Herranz Amo F, Verdu Tartajo F, Diez Cordero JM, Bueno Chomon G, Leal Hernandez F, Bielsa Carrillo A et al. Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml. Actas Urol Esp 1999; 23: 316–322.

    Article  CAS  PubMed  Google Scholar 

  11. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H et al. Prostate cancer screening in Tyrol, Austria: experience and results. Eur Urol 1999; 35: 523–538.

    Article  CAS  PubMed  Google Scholar 

  12. Monda JM, Barry MJ, Oesterling JE . Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151: 1291–1295.

    Article  CAS  PubMed  Google Scholar 

  13. Ornstein DK, Rao GS, Smith DS, Andriole GL . The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880–883.

    Article  CAS  PubMed  Google Scholar 

  14. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62: 451–455.

    Article  PubMed  Google Scholar 

  15. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD . Age and racial distribution of prostatic intraepithelial neoplasia. European Urology 1996; 30: 138–144.

    Article  CAS  PubMed  Google Scholar 

  16. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  PubMed  Google Scholar 

  17. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T . et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498–505.

    Article  PubMed  Google Scholar 

  18. Jones JS . Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 2007; 99: 1340–1344.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Denise Babineau, PhD, for her statistical assistance with this paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J S Jones.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, J., Follis, H. & Johnson, J. Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis 12, 57–60 (2009). https://doi.org/10.1038/pcan.2008.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.14

Keywords

This article is cited by

Search

Quick links